On February 7, 2023, the company signed a strategic cooperation agreement with Youjia (Hangzhou) Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as “Youjia Bio”). Guided by the principles of “innovative development and win-win cooperation,” the two parties will engage in deep strategic collaboration in areas such as the development of innovative gene-based drugs. Over the long term, the two sides will cooperate in fields including delivery systems, plasmid DNA, and siRNA drugs, leveraging their respective strengths to jointly advance the development of gene therapies and achieve a mutually beneficial common goal.

Dr. Cui Wenhao, founder of Youjia Bio, stated: NORTHLAND is an innovative biopharmaceutical company specializing in gene therapy drugs. It has been deeply engaged in the development of gene therapy drugs for a long time and has accumulated extensive experience in preclinical research, clinical studies, production and quality management, and pharmaceutical distribution. We believe that this collaborative partnership will help overcome some of the bottlenecks in gene therapy drug development, accelerate product development, and drive progress in the pharmaceutical industry.

Han Chengquan, Vice President of the company, stated: Gene therapies represent today’s most cutting-edge area in new drug development, and are continuously achieving breakthrough progress in the treatment of rare diseases, cancer, and chronic illnesses. Youjia Bio is a leader in China’s innovative small nucleic acid drug research and development, boasting a unique and mature delivery system and having established a leading nucleic acid drug CMC platform that can significantly shorten the drug development cycle and enhance the success rate of drug discovery. We look forward to long-term, in-depth cooperation between our two organizations, establishing a sustained communication mechanism, sharing drug development expertise and technological platforms, and forging a brand-new alliance in gene and nucleic acid drugs. Together, we will strive on this new frontier, developing more and better innovative medicines to benefit more patients.

About Youjia Bio

Youjia Biotechnology was co-founded by a team of overseas-trained PhDs and professionals with extensive experience in industrialization. The company is located in the Yangtze River Delta Biopharmaceutical International Industrial Park, Xiaoshan Economic and Technological Development Zone, Hangzhou City, Zhejiang Province. It boasts nearly 1,500 square meters of molecular biology and chemistry laboratories. Guided by the principle of meeting clinical needs and making innovative medicines affordable for the general public, Youjia Biotechnology’s product pipeline currently covers areas such as antiviral therapies, anti-fibrotic treatments, and cardiovascular diseases. The company has now established a mature, end-to-end development platform for nucleic acid drugs, encompassing an intelligent design system for nucleic acid drugs (NDDS), a drug evaluation system, a delivery system, and a nucleic acid drug CMC platform.